MedTrace Logo

Phase 1 Single Ascending Dose Study

NCT06934941 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-04-18

No results posted yet for this study

Summary

Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.

Conditions

  • Healthy Subjects

Interventions

DRUG

NM-101

NM-101 IV versus placebo

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Neuramedy Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-25
Primary Completion
2025-10-30
Completion
2026-03-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06934941 on ClinicalTrials.gov